GSK plc - 20 May 2021 Form 4 Insider Report for Innoviva, Inc. (INVA)

Reporting relationship: 10%+ Owner
Issuer ticker: INVA
Reported as of: 20 May 2021
Net transaction value: -$392,064,435
SEC form: 4
Accepted by SEC: 24 May 2021, 17:04:29 UTC
Next SEC filing: 04 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Victoria Whyte

Key filing fact

GSK plc filed Form 4 for Innoviva, Inc. (INVA) on 24 May 2021.

Key facts

This page summarizes GSK plc's Form 4 filing for Innoviva, Inc. (INVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 May 2021, 17:04.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$392,064,435.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INVA transaction

Common Stock

Sale

Transaction value: $392,064,435
Shares: -32,005,260
Change %: -100%
Price: $12.25
Shares after: 0
Date: 20 May 2021
Ownership: See Footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Common stock sold pursuant to a share repurchase agreement by and between Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of the Reporting Person, and Innoviva, Inc. (the "Issuer") dated as of May 20, 2021.

Footnote F2

Common Stock was held of record by GGL, an indirect wholly owned subsidiary of the Reporting Person.